About Tenax Therapeutics, Inc.
https://www.tenaxthera.comTenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada.
CEO
Christopher T. Giordano
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-01-03 | Reverse | 1:80 |
| 2023-01-05 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
IKARIAN CAPITAL, LLC
Shares:967.6K
Value:$17.68M
VR ADVISER, LLC
Shares:437.71K
Value:$8M
RTW INVESTMENTS, LP
Shares:378.35K
Value:$6.91M
Summary
Showing Top 3 of 39
About Tenax Therapeutics, Inc.
https://www.tenaxthera.comTenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $16.81M ▲ | $-15.8M ▼ | 0% | $-0.4 ▼ | $-15.8M ▼ |
| Q2-2025 | $0 | $11.79M ▲ | $-10.85M ▼ | 0% | $-0.27 ▲ | $-10.85M ▼ |
| Q1-2025 | $0 | $11.34M ▲ | $-10.41M ▼ | 0% | $-0.28 ▼ | $-10.41M ▼ |
| Q4-2024 | $0 | $7.29M ▲ | $-6.27M ▼ | 0% | $-0.18 ▲ | $-6.27M ▼ |
| Q3-2024 | $0 | $-4.62M | $-3.96M | 0% | $-0.19 | $-3.95M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $99.37M ▼ | $102.81M ▼ | $6.6M ▲ | $96.21M ▼ |
| Q2-2025 | $105.46M ▼ | $105.86M ▼ | $2.53M ▼ | $103.33M ▼ |
| Q1-2025 | $111.45M ▲ | $112.06M ▲ | $2.77M ▼ | $109.29M ▲ |
| Q4-2024 | $94.85M ▼ | $96.69M ▼ | $4.69M ▲ | $91.99M ▼ |
| Q3-2024 | $98.31M | $99.78M | $2.56M | $97.22M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-15.8M ▼ | $-9.15M ▼ | $0 | $3.06M ▲ | $-6.09M ▼ | $-9.15M ▼ |
| Q2-2025 | $-10.85M ▼ | $-6.26M ▲ | $0 | $278K ▼ | $-5.99M ▼ | $-6.26M ▲ |
| Q1-2025 | $-10.41M ▼ | $-6.97M ▼ | $0 | $23.56M ▲ | $16.6M ▲ | $-6.97M ▼ |
| Q4-2024 | $-6.27M ▼ | $-3.53M ▼ | $0 | $67.25K ▼ | $-3.46M ▼ | $-3.53M ▼ |
| Q3-2024 | $-3.96M | $-3.09M | $0 | $92.01M | $88.93M | $-3.09M |
Revenue by Products
| Product | Q4-2012 |
|---|---|
 United States | $0 ▲ |
Revenue by Geography
| Region | Q4-2012 |
|---|---|
 UNITED STATES | $0 ▲ |
CEO
Christopher T. Giordano
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-01-03 | Reverse | 1:80 |
| 2023-01-05 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
IKARIAN CAPITAL, LLC
Shares:967.6K
Value:$17.68M
VR ADVISER, LLC
Shares:437.71K
Value:$8M
RTW INVESTMENTS, LP
Shares:378.35K
Value:$6.91M
Summary
Showing Top 3 of 39